ArticleFrontiers in public health2022

Cost-effectiveness analysis of pembrolizumab vs. chemotherapy as second-line treatment for advanced esophageal carcinoma in the United States.

Jia Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.